BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech

  Latest News

Immunai and AstraZeneca Collaborate to Optimize Oncology Clinical Trials Using AI-driven Immune Mapping

by Andrii Buvailo, PhD  (contributor )   •   Sept. 26, 2024

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Industry Movers   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Immunai, a New York-based AI biotech company, has entered a multi-year collaboration with AstraZeneca to optimize oncology clinical trials. This partnership will use Immunai’s proprietary AMICA platform and Immunodynamics Engine (IDE)—technologies combining multi-omic single-cell data and advanced AI models of the immune system—to improve trial design and clinical decision-making.

#advertisement
AI in Drug Discovery Report 2025

Under the agreement, Immunai will receive $18 million for the initial phase, focusing on clinical trial optimization, including:

  • Dose selection
  • Mechanism of action elucidation
  • Patient responder vs. non-responder analysis
  • Biomarker identification

This collaboration builds on their previous work with AstraZeneca, which began in 2022, providing data-driven insights into several oncology programs. AstraZeneca has the option to extend the collaboration beyond the initial phase.

Immunai’s AMICA platform—the Annotated Multi-Omic Immune Cell Atlas—is claimed to be the world’s largest single-cell immune knowledge base, containing data from:

  • Tens of millions of cells across hundreds of disease settings
  • 5,000+ studies, including 350+ single-cell studies
  • 80+ immune cell types across 500+ diseases
  • 100,000+ patient samples

The IDE leverages this vast dataset to guide immune-modulating drug discovery by identifying patient subgroups, validating therapeutic hypotheses, and discovering new biomarkers. The platform integrates both public and proprietary datasets, combining functional genomics and dynamic data engineering for single-cell profiling and multiplexed perturbation studies.

Immunai has raised over $270 million in total funding, including a $215 million Series B round in 2021. The funds are fueling expansion beyond immuno-oncology into areas like autoimmune, cardiovascular, and neurological diseases.

Topic: Industry Movers

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.